Novel TCF4:TCF12 heterodimer inhibits glioblastoma growth

Abstract

TWIST1 (TW) is a pro‐oncogenic basic helix–loop–helix (bHLH) transcription factor and promotes the hallmark features of malignancy (e.g., cell invasion, cancer cell stemness, and treatment resistance), which contribute to poor prognoses of glioblastoma (GBM). We previously reported that specific TW dimerization motifs regulate unique cellular phenotypes in GBM. For example, the TW:E12 heterodimer increases periostin (POSTN) expression and promotes cell invasion. TW dimer‐specific transcriptional regulation requires binding to the regulatory E‐box consensus sequences, but alternative bHLH dimers that balance TW dimer activity in regulating pro‐oncogenic TW target genes are unknown. We leveraged the ENCODE DNase I hypersensitivity data to identify E‐box sites and tethered TW:E12 and TW:TW proteins to validate dimer binding to E‐boxes in vitro. Subsequently, TW knockdown revealed a novel TCF4:TCF12 bHLH dimer occupying the same TW E‐box site that, when expressed as a tethered TCF4:TCF12 dimer, markedly repressed POSTN expression and extended animal survival. These observations support TCF4:TCF12 as a novel dimer with tumor‐suppressor activity in GBM that functions in part through displacement of and/or competitive inhibition of pro‐oncogenic TW dimers at E‐box sites.